Saite, a subsidiary of Lukang Pharmaceutical (600789.SH), received a notice of approval for a supplementary application for resorcinol injections

Zhitong Finance App News, Lu Hang Pharmaceutical (600789.SH) announced that the company's holding subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. (“SAITE”) received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration and agreed that Sete will act as the marketing license holder for the above drugs.

According to reports, resorcinol injections are clinically used for acute spasmodic pain caused by digestive system and biliary tract dysfunction; acute spasmodic urethral, bladder, and renal colic; and gynecological spasmodic pain. Rectal triphenol acts directly on smooth muscle in the gastrointestinal tract and urogenital tract. It is a myotropic, non-atropine, and non-papaverine smooth muscle spasmolytic agent. Compared with other smooth muscle spasmolytics, it is characterized by not having an anticholinergic effect. While relieving smooth muscle spasms, it does not cause a series of anticholinergic side effects, does not cause symptoms such as low blood pressure, increased heart rate, or arrhythmia, and has no effect on cardiovascular function. All patients receiving intramuscular injection, static infusion, or intravenous drip administration have good adherence to long-term or high-dose medication.